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Case reports on two patients with episodic vertigo, 
ﬂuctuating hearing loss and migraine responding 
to prophylactic drugs for migraine.
Menière’s disease or migraine-associated vertigo?
Caso clinico di due pazienti con episodi di vertigine recidivante, ipoacusia 
ﬂuttuante ed emicrania con buona responsività alla terapia proﬁlattica
per l’emicrania. Malattia di Menière o vertigine emicranica?
R. TEGGI, B. FABIANO, P. RECANATI, P. LIMARDO, M. BUSSI
ENT Department, “San Raffaele” Hospital, “Vita-Salute” University, Milan, Italy
SUMMARY
Recent reports have focused on a possible association between migraine and Menière’s disease; patients suffering from Menière’s dis-
ease present a higher rate of migraine. In some cases, the clinical features of migraine-associated vertigo may mimic the presentation of 
Menière’s disease. The present report focuses on two cases of females with recurrent episodes of rotational vertigo,  uctuating hearing 
loss and tinnitus lasting from a few minutes to several hours; both cases also presented migrainous attacks. As a result of repeated cochleo-
vestibular attacks, both patients presented a permanent low frequency sensorineural hearing loss. Preventive therapies for Menière’s dis-
ease did not reduce vertigo attacks, while topiramate and acetylsalicylic acid treatment resulted in a signi cant reduction of both migraine 
and vertigo. Both the diagnosis of Menière’s disease and of migraine-associated vertigo rely on clinical history and both disorders lack a 
speci c diagnostic test. In the early stages, differential diagnosis between Menière’s disease and migraine-associated vertigo is often very 
dif cult; previous investigations focused on the possibility that subjects with migraine may experience all symptoms of Menière’s disease, 
including sensorineural  uctuating hearing loss. In conclusion, a trial with prophylactic drug treatment for migraine might be suggested in 
patients with clear symptoms of migraine and recurrent cochleovestibular disorders.
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RIASSUNTO
Recentemente la letteratura scienti ca ha posto l’attenzione sulla possibile associazione tra emicrania e malattia di Menière; pazienti 
affetti da malattia di Menière presentano una più alta incidenza di emicrania. In alcuni casi, le manifestazioni cliniche della vertigine 
emicranica possono mimare la presentazione della malattia di Menière. Presentiamo due casi di pazienti donne con episodi ricorrenti di 
vertigine rotazionale, ipoacusia  uttuante e acufene della durata variabile da minuti ad ore; entrambi i casi presentavano attacchi di emi-
crania. Come risultato di reiterati attacchi cocleovestibolari, i pazienti presentavano ipoacusia neurosensoriale permanente per le basse 
frequenze. La terapia di prevenzione per la malattia di Menière non riduceva gli attacchi vertiginosi, mentre la somministrazione di topi-
ramato e acido acetilsalicilico determinava una drastica riduzione sia dell’emicrania sia della vertigine. Entrambe le diagnosi di malattia 
di Menière e vertigine emicranica si basano sulla storia clinica e non posseggono test diagnostici speci ci. Negli stadi precoci, la diagnosi 
di differenziale tra malattia di Menière e vertigine emicranica è spesso piuttosto dif coltosa; lavori precedenti sottolineano la possibilità 
che soggetti affetti da emicrania possono manifestare tutti i sintomi di malattia di Menière, inclusa l’ipoacusia neurosensoriale  uttuante. 
In conclusione, una terapia farmacologica pro lattica per emicrania potrebbe essere consigliata nei soggetti con franca sintomatologia 
emicranica associata a disordini cocleovestibolari ricorrenti.
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Introduction
Menière’s disease (MD) is an inner ear disorder charac-
terized by recurrent episodes of rotational vertigo, most 
typically associated with  uctuating progressive hearing 
loss, typically on low frequencies in early stages, fullness 
and tinnitus. Raised endolymphatic pressure (hydrops) is 
commonly accepted as the causal condition 1 2.
Criteria used to de ne MD are: the presence of at least 
two episodes of vertigo of at least 20 minutes’ duration, 
audiometrically con rmed sensorineural hearing loss on 
at  least  one  occasion,  tinnitus  or  aural  fullness  during 
episodes and exclusion of other possible causes of ver-
tigo 3. Prosper Menière himself observed the association 
between MD and migraine 4.R. Teggi, et al.
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Various studies have focused on the higher prevalence 
of  migraine  in  MD  patients,  variously  reported  at  be-
tween 43% and 56%, while in the normal population it 
is 10% 5 6.
On the other hand, there is a higher prevalence of MD 
in a population screened for migraine compared to the 
incidence in the general population 7. Epidemiology of 
both  MD  and  migraine-associated  vertigo  (MAV)  may 
underline a possible pathogenetic link between the 2 dis-
eases 8 9.
Migraine is an increasingly recognized cause of recurrent 
vestibular symptoms; features of MAV include both true 
rotational vertigo and subjective vertigo lasting from a 
few minutes to days. During attack-free periods, several 
studies have documented vestibular anomalies in 30-55% 
of subjects 10-12.
According to Neuhauser et al. 13, diagnostic criteria for 
de nite MAV are:
r FQJTPEJDWFTUJCVMBSTZNQUPNTPGBUMFBTUNPEFSBUFTF-
verity (rotational vertigo, other illusory self or object 
motion, positional vertigo, head motion intolerance);
r BU MFBTU UXP PG UIF GPMMPXJOH NJHSBJOPVT TZNQUPNT
during at least two vertiginous attacks: (a) migrainous 
headache, (b) photophobia, (c) phonophobia, (d) visual 
or other aurae;
r BUUBDLTPGNJHSBJOF	JOEFQFOEFOUMZPGFQJTPEFTPGWFSUJ-
go) according to International Headache Society (IHS) 
criteria;
r TPNFDFOUSBMBOEPSQFSJQIFSBMWFTUJCVMBSBCOPSNBMJUJFT
found in vertigo-free periods.
MAV is the main disorder capable of mimicking MD in its 
early stages. There is clinical evidence that migraine can 
damage the inner ear, causing permanent hearing loss or 
impairment of vestibular function 14 15. Some authors have 
hypothesized that MD may develop in an ear previously 
damaged by vasospasm induced by migrainous mecha-
nisms 16.
The present report refers to two migrainous patients, pre-
senting with repeated episodes of rotational vertigo with 
permanent sensorineural hearing loss ful lling all of the 
criteria for de nite MD; their response to treatment for 
MD was poor whilst they showed a satisfactory response 
to prophylactic drugs for migraine.
Case reports
Case 1
This patient, a 42-year-old female, was suffering from 
migraine with aura according to IHS criteria. The  nal 
diagnosis was made by a senior neurologist. The patient 
reported the  rst attack of migraine at the age of 20 years, 
which  more  typically  occurred  before  menstruation,  at 
a frequency of 1-2/month. Her family history was posi-
tive for migraine (mother and one of three sisters). Blood 
tests showed repeated positivity for lupus-like anti-coag-
ulants; anti-nuclear, anti-mitochondria, anti-thyroid, anti-
cardiolipin auto-antibodies and rheumatoid factor, on the 
other hand, resulted negative. She also presented normal 
C-reactive protein (CRP), erythrocyte sedimentation rate 
(ESR), serum protein electrophoresis, a normal aPTT and 
normal C3 and C4 levels. Central nervous system nuclear 
magnetic resonance (NMR) imaging demonstrated micro-
ischaemic lesions. High resolution computerized tomog-
raphy (CT) scan was normal. She was not receiving any 
pharmaceutical treatment for migraine at the time of our 
evaluation.
In the previous 2 years, the patient reported recurrent epi-
sodes of rotational vertigo (about 1/month) lasting from a 
few minutes to 1-2 hours, often with a right ear  uctuating 
hearing loss. Migraine and vertigo never occurred togeth-
er. As a  nal result, her audiometric threshold showed a 
right sided low frequency sensorineural hearing loss. Pure 
tone audiometry (PTA) average at 250-500 and 1000 Hz 
was 35 db, while PTA average at 1-2 and 3 KHz was 15 
db. She also reported the presence of tinnitus which in-
creased before vertigo attacks. Acoustic evoked potentials 
were normal. As a result of the short duration of vertigo, 
we were unable to perform an audiometric examination 
during  vertigo  attacks.  Her  left  ear  showed  a  normal 
threshold. Caloric tests demonstrated a right sided unilat-
eral weakness (26%) during caloric stimulation accord-
ing to Freyss and the Head Impulse Test was positive on 
the horizontal plane with re xation saccades towards the 
left side. Vestibular evoked myogenic potentials (VEMPs) 
were also recorded with an ipsilateral technique, using a 
short broadband click of 0.1 msec duration, while the sub-
ject was seated upright with her chin turned towards the 
controlateral shoulder. Ongoing EMG activity was visu-
ally monitored on an oscilloscope to ensure tension on the 
sternocleidomastoid muscle greater than 65 NV during re-
cording. The patient presented normal bilateral broadband 
click-evoked cervical VEMPs for latency and amplitude; 
on the other hand, she presented a normal 120 db SPS 
(Sound Pressure Level) threshold on the unaffected side 
but a 10 db threshold shift on the right side.
Case 2
This patient, a 59-year-old female with a long history of 
migraine which began at the age of 23 and ceased at the 
age of 50, immediately after onset of menopause. She 
had normal blood tests (above all rheumatologic tests), 
normal central nervous system NMR imaging and normal 
high resolution inner ear CT scan. Over the last year, she 
reported various episodes of rotational vertigo normally 
lasting for 2-3 hours with hearing loss on the left side. 
She  reported  increased  hearing  loss  during  vertigo. 
Audiometric examinations demonstrated a low frequency 
sensorineural  hearing  loss  (PTA  at  250-500  and  1000 
HZ 30 db while PTA at 1-2 and 3 KHz 20 db); acoustic-
evoked potentials presented normal latencies. Caloric tests Menière’s disease or migraine-associated vertigo?
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according to Freyss demonstrated a unilateral weakness 
of 40%; Head Impulse Test was positive with corrective 
saccades towards the right side on the horizontal plane.
Cervical VEMPs were normal for latency, amplitude and 
threshold.
The two patients ful lled all AAOHNS criteria for de nite 
MD. In both cases, preventive therapy of MD with betahis-
tine 24 mg twice a day, salt restriction and increased water 
intake did not prevent vertigo attacks, which remained un-
changed in frequency and duration in a 6-month follow-
up. On the other hand, drug prophylaxis of migraine with 
topiramate 100 mg a day and disaggregants (acetylsali-
cylic acid 100 mg a day) produced a clear decrease in ver-
tigo attacks, in both patients, in a 1-year follow-up, since 
patient 1 did not report any episodes of vertigo and patient 
2 reported only one mild episode of about 10 min. Patient 
1 also reported a reduction in migraine attacks since she 
reported only one mild episode. Dietary changes, to re-
duce the triggers for migraine (above all caffeine, choco-
late and red wine), were suggested to both patients.
In both cases, the audiometric thresholds remained con-
stant.
Discussion
The signs and symptoms of MAV sometimes show an 
overlap with those of MD; in these cases, differential di-
agnosis is often dif cult. Both MD and MAV diagnoses 
rely considerably on history and both disorders lack a 
de nite diagnostic test. It should be noted that, at present, 
“hearing is the most readily measured variable and the 
variable most related to the natural history of Menière’s 
disease” 3.
Previous investigations have focused on case studies in 
which differentiating between the two disorders is a puz-
zling dilemma 17.
Vestibular anomalies, such as spontaneous or positional 
nystagmus, failed to offer a reliable test to differentiate the 
2 disorders; percentage of asymmetric caloric responses, 
reported in an average of 24.5% of cases of MAV, magni-
tude of unilateral weakness and rotational tests have not 
been reported to be useful in discriminating between the 
two disorders 10 18.
Patients with MAV may experience all the symptoms of 
MD, including  uctuating sensorineural hearing loss 19, 
even though repeated MAV attacks very rarely produce a 
permanent hearing loss 20.
A  uctuating hearing loss in children has been consid-
ered, by some authors, as a migraine equivalent 21.
As also in our two patients, the majority of patients with 
MAV have attacks of dizziness independently of migraine 
headache; it should be noted that in our second patient, 
vertigo spells began when migrainous attacks ceased 22 23.
Topiramate blocks voltage-sensitive sodium channels and 
voltage-activated calcium channels, inhibits glutamate re-
lease, and increases GABA levels 24. Some large studies 
have demonstrated that topiramate is a safe, effective, and 
well-tolerated drug for migraine prophylaxis. Above all, 
few side-effects are described when topiramate is used at 
doses up to 100 mg a day 25 26.
These cases underline that there are some doubts concern-
ing the statement that “ uctuating hearing loss with ver-
tigo is almost always due to Menière’s disease”, moreover 
the pathophysiological conditions of MD and MAV are 
poorly understood 4 27.
Some  further  considerations  should  be  added  regard-
ing lupus anti-coagulant (LAC) positivity, white matter 
micro-ischaemic  lesions  and  migraine.  LAC  positivity, 
as well as the presence in blood of anti-cardiolipin and 
C2-glycoprotein I antibodies, is widely known as the an-
tiphospholipid syndrome; the main characteristic of the 
disease  is  an  antibody-mediated  hypercoagulable  state 
characterized by recurrent venous and arterial thrombo-
embolic events. Primary antiphospholipid syndrome refers 
to patients who do not have any other rheumatologic or 
autoimmune conditions, whereas secondary antiphospho-
lipid syndrome refers to patients who also have systemic 
lupus erythematosus (SLE) or other conditions. In gener-
al, the clinical manifestations of the antiphospholipid syn-
drome are similar for primary and secondary forms of the 
disease 28. Antiphospholipid antibodies are found among 
young, apparently healthy control subjects at a prevalence 
of 1 to 5%. Cerebro-vascular events have been reported 
to  be  positively  associated  with  the  antiphospholipid 
syndrome 29 30. An association between Behcet’s Disease 
and cerebral blood  ow perfusion impairment has been 
demonstrated with a SPECT examination even in subjects 
with normal MRI  ndings 31. A possible role of antiphos-
pholipid antibodies, in the pathogenesis of migraine, is 
still under debate. No association has been found between 
anti-cardiolipin autoantibodies and migraine in a paediat-
ric population 32, while in adults, with some exceptions 33, 
the prevalence of migraine, above all with aura, has been 
reported to be higher in SLE subjects than in the normal 
population 34-38, and an association with antiphospholipid 
syndrome has been suggested 39. The American College 
of Rheumatology included headache and migraine among 
the neuro-psychiatric syndromes observed in SLE 40.
More  frequently,  in  autoimmune  disorders,  neurologic 
involvement is reported to be present in between 4 and 
49%, and, moreover, in 5% of cases, it is the initial fea-
ture; immuno-mediated disease activity may justify the 
higher prevalence of migraine in autoimmune disorders 
and the cerebral MRI  ndings 41 42.
The overlapping signs and symptoms between MD and 
MAV have caused some Authors to suggest the possibil-
ity of a common link in the pathogenesis of the two dis-
eases.
As the vestibular nuclei receive noradrenergic  bres from 
the locus coeruleus 43 and serotonergic afference from the R. Teggi, et al.
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dorsal raphe nucleus 44, it is likely that activation of these 
pathways, in migraine, could also activate central vestibu-
lar processing 45. Moreover, the reciprocal connection of 
vestibular nuclei and trigeminal nucleus caudalis may pro-
vide a close link between vestibular and vascular-trigem-
inal processing during migraine attacks and trigeminal 
inner ear sensory innervation may explain the peripheral 
neuro-otological disorders. Short duration vertigo may be 
related to vasospasm-induced ischaemia of the labyrinth 
and repeated episodes may lead to irreversible damage 46. 
Moreover, it has been suggested that endo-lymphatic hy-
drops may develop in an ear previously compromised by 
vasospasm due to a migrainous mechanism 14.
Shepard 17 suggested the following practical criteria in or-
der to differentiate MD and MAV:
r 5IF VTF PG B DPOTJTUFOU BOE WFSJàBCMF EFàOJUJPO PG
MAV  is  important  for  consistency  and  comparison 
across facilities and clinical trials regarding diagnoses 
and treatment. MAV must be considered as part of the 
differential diagnosis.
r *OUIFQBUJFOUTIJTUPSZ
UIFSFQPSUPGPOMZWFSZTIPSU	TFD-
onds to less than 15 minutes) or prolonged (more than 
24 hours) vertigo spells are more likely due to migraine 
rather than MD. Moreover, if the spontaneous spells of 
vertigo are associated with migraine features (phono- or 
photo-phobia), migraine is the probable source.
r *O ."7
 BVEJPNFUSJD BOE WFTUJCVMBS BOPNBMJFT BSF
more typically mild in magnitude and stable over time 
rather than  uctuating.
As a  nal personal consideration, when symptoms coexist 
with migraine, a trial with a migraine management regi-
men is suggested. MAV is, above all, a diagnosis of ex-
clusion based on clinical history 47. It should be of some 
importance, the idea that aggressive drug treatment for 
migraine is anyway more mild than aggressive treatment 
for MD.
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